NeuroPace, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
November 08, 2022 at 04:06 pm EST
Share
NeuroPace, Inc. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was USD 11.16 million compared to USD 10.34 million a year ago. Net loss was USD 11.79 million compared to USD 8.08 million a year ago. Basic loss per share from continuing operations was USD 0.48 compared to USD 0.34 a year ago.
For the nine months, sales was USD 32.73 million compared to USD 34.19 million a year ago. Net loss was USD 35.94 million compared to USD 25.39 million a year ago. Basic loss per share from continuing operations was USD 1.47 compared to USD 1.81 a year ago.
NeuroPace, Inc. is a medical device company. The Company is focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is a brain-responsive platform that delivers personalized, real-time treatment at the seizure source. The Company has developed its RNS System to address the individualized nature of drug-resistant epilepsy and deliver a safe therapy for focal onset seizures anywhere in the brain. The RNS System is a device that records brain activity data and allows clinicians to monitor patients not only in person, but also remotely. RNS System monitors and analyzes the brainâs electrical activity, recognizes patient-specific abnormal patterns, and delivers treatment at the seizure source. The Companyâs RNS System is also engaged in treating other brain disorders, including depression, impulse control disorders, memory disorders, and post-traumatic stress disorder.
NEUROPACE, INC. 
